|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 39/39 | |
| A61K 39/395 | |||
| A61K 31/00 | |||
| A61K 38/00 | |||
| A61P 13/12 |
| (11) | Number of the document | 1715890 |
| (13) | Kind of document | T |
| (96) | European patent application number | 05713358.9 |
| Date of filing the European patent application | 2005-02-11 | |
| (97) | Date of publication of the European application | 2006-11-02 |
| (45) | Date of publication and mention of the grant of the patent | 2008-07-09 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2005/004367 |
| Date | 2005-02-11 |
| (87) | Number | WO 2005/077413 |
| Date | 2005-08-25 |
| (30) | Number | Date | Country code |
| 544121 P | 2004-02-11 | US | |
| 561018 P | 2004-04-08 | US | |
| 578401 P | 2004-06-09 | US | |
| 620802 P | 2004-10-20 | US |
| (72) |
FLYVBJERG, Allan, DK
GUO, Guangjie, US
LIU, David, Y., US
NEFF, Thomas, B., US
OLIVER, Noelynn, A., US
USINGER, William, R., US
WANG, Qingjian, US
|
| (73) |
FIBROGEN, INC.,
225 Gateway Boulevard, South San Francisco, CA 94080,
US
|
| (54) | CTGF AS TARGET FOR THE THERAPY OF MICROALBUMINURIA IN PATIENTS WITH DIABETIC NEPHROPATHY |
| CTGF AS TARGET FOR THE THERAPY OF MICROALBUMINURIA IN PATIENTS WITH DIABETIC NEPHROPATHY |